AI-Generated Drug May Slow Aging, Study Finds
Rentosertib shows promise in reducing biological age markers.
1AI-Driven Drug Discovery
Insilico Medicine, an AI-focused drug development company, has created rentosertib, a drug initially aimed at treating chronic lung disease. The company also explored its potential to extend lifespan. Using AI, Insilico identified biological markers of aging and developed rentosertib to target them. This marks a significant step in leveraging AI for drug discovery and aging research.
2Aging Clocks as Metrics
Aging clocks, once metaphorical, have evolved into measurable tools assessing morbidity and mortality. These clocks use biomarkers, physiological metrics, and psychological assessments to estimate biological age. AI has enhanced their accuracy by analyzing diverse data points. Despite their potential, aging clocks remain debated, with scientists working to refine their reliability for research purposes.
3Study Design and Participants
The study involved 42 participants over a 12-week trial. Participants receiving rentosertib showed reduced biological age markers, while those on placebo or no treatment saw no change or an increase. Six different aging clocks were used to measure outcomes, revealing consistent shifts. This suggests rentosertib may impact multiple dimensions of biological aging.
4Rentosertib’s Dual Purpose
Rentosertib was developed to treat chronic lung disease and potentially extend lifespan. The study highlights its ability to reduce biological age markers, offering hope for broader applications. This dual focus underscores the versatility of AI-generated drugs in addressing complex health challenges.
5Variations in Aging Clocks
Aging clocks vary in methodology, from tracking DNA methylation to measuring blood proteins. Early models focused on chemical changes in DNA, while newer ones emphasize proteomics. A 2024 study found blood proteins could predict age-related disease risks. Despite advancements, no universally accepted aging clock exists yet.
6Debate Over Aging Clocks
While aging clocks hold promise, their utility remains contested. Researchers aim to improve their accuracy for meaningful applications. Current models provide insights but lack universal acceptance. The field continues to evolve, with scientists striving to establish reliable markers for aging research.
7Implications for Aging Research
Rentosertib’s success in reducing biological age markers could revolutionize aging research. It demonstrates AI’s potential to identify and target aging-related biomarkers. This breakthrough may pave the way for future therapies aimed at extending healthy lifespans and combating age-related diseases.
8Future of AI in Medicine
The study highlights AI’s transformative role in drug discovery and aging research. Rentosertib’s development showcases how AI can accelerate innovation and address complex health issues. As AI continues to advance, its applications in medicine promise to reshape healthcare and improve longevity.
Original article: Gizmodo — AI-Generated Drug May Slow Aging, Study Finds